U.S. Marine and Shipping Stock News

Cardinal Health (CAH) has seen a sustained uptick in its share price recently, with the stock rising over 38% in the past 3 months. Investors are taking notice as momentum continues, partly due to solid financial results and steady growth. See our latest analysis for Cardinal Health. Cardinal Health’s recent share price momentum is hard to miss, with a 31.8% gain over the past month helping to drive a stellar 74.7% year-to-date share price return. That strength builds on an impressive...

Builders FirstSource (BLDR) stock has seen some sharp swings over the month, dropping about 19%. Investors are likely weighing the underlying trends, including revenue growth of just 2% and a stronger increase in net income year over year. See our latest analysis for Builders FirstSource. After a solid run in earlier years, Builders FirstSource has lost momentum lately, with its 1-year total shareholder return down 44.2%. While the latest 30-day share price return of -18.9% reflects shifting...

Wondering whether Agnico Eagle Mines is worth your hard-earned cash right now? You're not alone, and a closer look could reveal whether the recent buzz is justified. The stock may have dipped slightly with a 1.8% decline over the past week and a 5.5% change for the month, but the year-to-date climb of 101.2%, and a notable 109.4% return in the last 12 months, certainly catches the eye. News cycles are lighting up around gold miners lately, which has definitely added to Agnico Eagle Mines'...

Earlier this month, the Chinese Ministry of Commerce lifted its export ban on Illumina, Inc., though the company remains on the Unreliable Entities List, requiring government approval for instrument purchases. This regulatory shift allows Illumina to resume some business activity in China, which has been a significant market for the company's genomics solutions and growth strategy. We'll explore how renewed market access in China may influence Illumina's investment narrative and future...

EyePoint Pharmaceuticals (EYPT) just released third-quarter earnings, revealing that revenue fell sharply to $0.97 million from $10.5 million last year. Net loss nearly doubled during the same period. See our latest analysis for EyePoint Pharmaceuticals. Shares of EyePoint Pharmaceuticals have maintained solid momentum in 2024, with a year-to-date share price return of 44.2% and a 1-year total shareholder return of nearly 35%. While there was a dip in quarterly revenue, investors appear...

Asana (ASAN) shares recently moved lower, catching the eye of investors trying to make sense of its ongoing slide over the past month. The company’s stock has struggled to gain traction so far this year, which has drawn attention to its current valuation and future outlook. See our latest analysis for Asana. After a challenging start to the year, Asana’s 1-day share price return of -5.28% and 7-day slide of -11.09% highlight mounting investor caution, with recent declines adding to an already...

On November 17, 2025, H World Group Limited reported its earnings for the nine months ended September 30, 2025, with revenue rising to CNY 6.96 billion and net income increasing to CNY 1.47 billion, while also providing revenue growth guidance of 2%-6% for the fourth quarter compared to the same period last year. Management highlighted fourth quarter revenue expectations both including and excluding the DH business, providing investors with a transparent view into performance drivers and...

Ever wondered if Mirion Technologies is offering great value, or if this growth story is already reflected in the share price? Let’s break down what really matters for investors looking to buy or hold. While Mirion’s share price surged 308.5% over the last 3 years and is up 44.1% year-to-date, it recently took a 10.1% dip over the past week, which may indicate shifting market sentiment. News such as Mirion finalizing new partnerships in the medical imaging space and expanding its footprint...

Peabody Energy (NYSE:BTU) shares slipped a little this week, with the stock down about 5% over the past month. For investors, this invites a closer look at what is driving recent price action and how valuations stack up. See our latest analysis for Peabody Energy. Looking beyond the recent 5% slide, Peabody Energy continues to show strong momentum in 2024. The share price is up more than 36% year-to-date, and shareholders have seen a 9% total return over the past year. Even as short-term...

Vail Resorts (MTN) shares have slipped over the past month, dropping about 7%, and are now trading near $140. Investors are watching to see how the company navigates market headwinds and whether a turnaround is in sight. See our latest analysis for Vail Resorts. The recent slide in Vail Resorts’ share price continues a year marked by fading momentum, with a 1-year total shareholder return of -16.35% and a 5-year total return of -40.26%. Despite flashes of growth in revenue and net income,...

SentinelOne (S) recently introduced a suite of new AI-powered cybersecurity solutions and integrations at its OneCon 2025 event. The company is partnering with both Amazon Web Services and Google Threat Intelligence to address rapidly evolving security needs in the cloud and AI sectors. See our latest analysis for SentinelOne. While SentinelOne has made headlines with its flurry of AI security launches and new partnerships, the excitement has not yet translated into stock gains. The 1-year...

Merit Medical Systems (MMSI) is attracting investor attention after sharing strong trial results for its WRAPSODY device. However, the company is also facing a delay in U.S. reimbursement approval, which pushes possible incremental payments out to 2027. See our latest analysis for Merit Medical Systems. Following these key updates, Merit Medical Systems’ 1-day share price return edged up 0.8%, while the 1-year total shareholder return remains in negative territory at -17.5%. Positive momentum...

Dynavax Technologies Corporation recently announced a US$100 million share repurchase program, reported its third quarter 2025 earnings, and reiterated full-year net product revenue guidance for HEPLISAV-B of US$315 million to US$325 million. This series of updates highlights both management’s ongoing confidence in the core hepatitis B franchise and a renewed emphasis on capital returns to shareholders. Let’s explore how the newly announced share repurchase program may influence Dynavax's...

Luckin Coffee announced its third quarter 2025 results, reporting a 50.2% year-over-year increase in net revenues and record average monthly transacting customers, while expanding its store network to over 29,000 locations as of quarter-end. This expansion enabled Luckin to reach new customer records and reflects a focus on scale, product innovation, and a value proposition centered on affordability and convenience. We'll explore how Luckin Coffee's accelerating store expansion and customer...

Rapport Therapeutics recently reported third-quarter 2025 earnings, disclosing a net loss of US$26.93 million, which was larger than its loss for the same quarter last year. While quarterly losses widened, the nine-month basic loss per share improved to US$2.15 compared to US$3.66 for the same period a year ago. We'll explore how the company's expanding quarterly losses shape the current investment narrative for Rapport Therapeutics going forward. Find companies with promising cash flow...

Wondering whether Avantor could offer you a bargain right now? You are not alone, as many investors are questioning if its recent slide presents a hidden opportunity or a warning sign. Avantor's share price has taken a sharp turn recently, dropping 26.4% over the last month and tumbling nearly 49% year-to-date, which suggests that market sentiment and risk perceptions have shifted significantly. Recently, headlines have centered on sector-wide pressures affecting life sciences suppliers and...

In November 2025, Johnson & Johnson announced several significant milestones, including FDA approvals for new indications of DARZALEX FASPRO® and CAPLYTA, as well as positive Phase 3b data for TREMFYA® in psoriatic arthritis. These regulatory advances highlight the continuing expansion of Johnson & Johnson's pharmaceutical portfolio across oncology, immunology, and neuropsychiatry. Particularly, the approval of DARZALEX FASPRO® as the first treatment for high-risk smoldering multiple myeloma...

WeRide (NasdaqGM:WRD) has just gained approval to run fully driverless robotaxi services in Abu Dhabi. This permit removes the requirement for an onboard safety driver and represents a significant advance in international autonomous vehicle operations. See our latest analysis for WeRide. Despite major regulatory wins and tech breakthroughs this year, WeRide’s momentum has been clouded by steep declines, with a year-to-date share price return of -50.5% and a one-year total shareholder return...

CareTrust REIT (CTRE) just posted its third-quarter results, showing marked gains in both revenue and net income from a year earlier. The company also raised its earnings guidance for 2025, which has drawn fresh attention from investors. See our latest analysis for CareTrust REIT. CareTrust REIT’s upbeat earnings and higher guidance have not gone unnoticed, with the share price climbing 37.18% year-to-date. Momentum has gathered pace following recent results, and the stock’s 1-year total...

ReNew Energy Global (NasdaqGS:RNW) has just announced a sweeping $9.33 billion investment to broaden its renewable projects in Andhra Pradesh. This comes alongside headline financial results and fresh financing that are shaping investor expectations around the company’s next phase of growth. See our latest analysis for ReNew Energy Global. All eyes have turned to ReNew’s bold expansion plans and high-profile funding wins, which arrive amid a year of growing optimism. The 1-year total...

Ever wondered if Lantheus Holdings might be undervalued, or if the recent volatility is creating an opportunity you do not want to miss? After a bumpy year with the stock down 40.3% year-to-date and 30.5% over the last 12 months, Lantheus Holdings managed a 4.6% price increase in the past week, suggesting a potential shift in sentiment or new factors influencing the market. Recent news about advancements in the company's diagnostic imaging portfolio and its expansion into emerging markets...

Wondering if NetApp stock is good value right now? You are not alone, especially with many investors trying to determine where this tech company fits in today's market. NetApp's share price has dipped recently, losing 2.7% over the past week and 8.1% in the past month. However, those who held on for the last three or five years have still seen gains of 61.5% and 130.6%, respectively. Recent news has highlighted both industry-wide challenges and the ongoing shift toward cloud services. NetApp...

Valvoline Inc. recently appointed Hitesh Patel as its Chief Technology and Cybersecurity Officer, effective November 3, 2025, bringing deep retail technology and cybersecurity experience from roles at Sleep Number, Advance Auto Parts, and Best Buy. This leadership change underscores Valvoline's aim to strengthen its technology and cybersecurity capabilities as it continues to expand operationally and embrace digital transformation across its service network. We'll examine how the addition of...

National Vision Holdings (EYE) laid out its investment roadmap and growth targets this week, unveiling new plans to accelerate store openings and confirming multi-year guidance through 2030. This clarity may be fueling investor interest. See our latest analysis for National Vision Holdings. National Vision Holdings’ share price has more than doubled so far this year with a year-to-date gain of 120.1%. This dramatic turnaround coincides with its upbeat guidance and expansion plans. Recent...